Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
- Conditions
- MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 327
- Registration Number
- NCT05838768
- Locations
- 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸University of California LA, Los Angeles, California, United States
🇺🇸UCSF, San Francisco, California, United States
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
- Conditions
- IgA NephropathyImmunoglobulin A Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT05834738
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸Hospital del Vall d´Hebron, Barcelona, Spain
🇪🇸Hospital Ribera Polusa, Lugo, Spain
A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in India
- Conditions
- Neurovascular Age-related Macular Degeneration
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT05834075
- Locations
- 🇮🇳
Disha Eye Hospital, Kolkata, India
🇮🇳Dr. Milan's Retina Care Center, Rajkot, India
🇮🇳Susrut Eye Foundation and Research Center, Kolkata, India
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 297
- Registration Number
- NCT05833022
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Cristiana Care, Wilmington, Delaware, United States
🇺🇸All Children's Hospital, Saint Petersburg, Florida, United States
Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
- Conditions
- Secondary Progressive Multiple Sclerosis
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 368
- Registration Number
- NCT05826028
- Locations
- 🇦🇺
Novartis Investigational Site, St Leonards, New South Wales, Australia
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Conditions
- Early Breast Cancer
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1400
- Registration Number
- NCT05827081
- Locations
- 🇺🇸
Ocala Research Institute, Inc, Ocala, Florida, United States
🇺🇸Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸Washington Hospital Center, Washington, District of Columbia, United States
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT05816720
- Locations
- 🇺🇸
Excel Diagnostics & Nuclear Oncology Center, Houston, Texas, United States
Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)
- Conditions
- Diabetic Macular Edema
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT05815212
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
Safety and Efficacy of RHH646 for Knee Osteoarthritis
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 82
- Registration Number
- NCT05816395
- Locations
- 🇺🇸
Clinical Trial Network, Houston, Texas, United States
🇺🇸Pioneer Research Solutions, Sugar Land, Texas, United States
🇺🇸Clinical Trials Research, Lincoln, California, United States
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Other: Ofatumumab
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 174
- Registration Number
- NCT05809986
- Locations
- 🇵🇹
Novartis Investigative Site, Setubal, Portugal